GLP-1 receptor agonists reduce cardiovascular event risk independent of weight loss in type 2 diabetes

Marso SP, Bain SC, Consoli A, et al. • New England Journal of Medicine • PMID SEED004

Rate this summary
★ ★ ★ ★ ★
✨ AI-Generated Summary

New analysis of a major diabetes drug trial shows that semaglutide protects the heart through mechanisms beyond just weight loss, suggesting the drug has direct cardiovascular benefits that could apply to patients regardless of obesity status.

⚠ AI summaries are generated automatically and may contain errors. Always refer to the original abstract and full article for clinical or research decisions.

Abstract

A pre-specified mediation analysis of the SUSTAIN-6 trial (n=3,297) demonstrated that semaglutide reduced major adverse cardiovascular events by 26% compared to placebo, with only 12% of the benefit attributable to body weight reduction.

← All Research
How would you rate this summary?
Your feedback helps us improve the quality of our AI summaries.
★ ★ ★ ★ ★
What did you like about this summary?
What did you not like about this summary?
Anything else you'd like to see covered?
Report an error
All reports are reviewed before any changes are made.
What type of error are you reporting?
Which part does this relate to?
Please describe the error
Be as specific as possible — include the correct information if you know it.
Highlight mode — select the text containing the error
Click and drag over the relevant text, then click Confirm.
✓
Thank you
Your response helps us improve the quality of our AI summaries.